Arcellx, Inc. (ACLX) Stock

Arcellx, Inc. is a clinical-stage biotechnology company developing innovative cell therapies for patients with cancer and other incurable diseases. Its lead product candidate, anitocabtagene autoleucel (anito-cel), utilizes the proprietary ddCAR platform and is in phase 3 clinical trials for relapsed or refractory multiple myeloma, featuring D-Domain technology for enhanced control and safety. The company advances ACLX-001, targeting BCMA in phase 1 for the same indication via the ARC-SparX platform, and ACLX-002 in phase 1 against CD123 for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. Preclinical efforts include ACLX-003 for AML and MDS, alongside programs for solid tumors. Arcellx maintains a strategic collaboration with Kite Pharma, a Gilead company, to co-develop and co-commercialize anito-cel. Founded in 2014 and headquartered in Redwood City, California, Arcellx focuses on engineering safer, more effective, and accessible immunotherapies to transform cancer treatment.